A recently completed phase 2 trial in obese and non-diabetic individuals revealed, according to a press release, that danuglipron at doses ranging from 40 to 200 mg twice daily resulted in a 11.7% weight loss after 32 weeks of treatment compared to placebo
This makes it an attractive option for men who are seeking a less invasive treatment alternative for BPH, particularly those who are not ideal candidates for surgery due to other health concerns
BPC-157 is discussed here as a research peptide with compound-identity, purity, COA, and analytical-testing considerations, not as a consumer product
Biomed Pharmacother 2003
If left untreated, the deficiency can cause severe neurologic problems and blood diseases
As it turns out, we still have more questions than answers about trendy peptide injections